- Business segment: Service Provider
- LEUKOCARE AG
- Am Klopferspitz 19
- 82152 Planegg/Martinsried
- Phone: +49 (0)89/780 16 65–0
- Fax: +49 (0)89/780 16 65–11
Michael Scholl, CEO
LEUKOCARE, founded in 2003 by Prof. Martin Scholz and Michael Scholl, is a team of highly dedicated scientists and business people committed to delivering the best services, technologies and solutions to customers and partners. We are pushing the boundaries of drug product development by combining innovative biostatistics, artificial intelligence and vast expertise of formulations with first-class analytics. Guided by a long-standing history of stabilizing complex biological compounds, we apply our technologies and in-house developed algorithms to offer our customers reliable and fast solutions tailored to their needs.
What is your motivation?
We support our partners during the development of innovative drug products. Our mission is to improve the drug product characteristics of biopharmaceuticals so that physicians and patients can benefit from it. LEUKOCARE’s formulation technologies facilitate the use of biopharmaceuticals, benefits are: higher stability and increased shelf life of biopharmaceutical products, allowance for storage at room temperature – no need for cold chain logistics, higher concentrations allowing for convenient forms of application; and self-administration by the patient – no need to go to a hospital.
“Since the time we moved to the IZB, our headcount grew steadily from 6 to 60 employees. The IZB supported us continuously and we look forward to being part of the IZB in future.”
Michael Scholl, CEO
LEUKOCARE is a privately owned, product-focused, clinical-stage biotechnology company founded in 2003. In 2010, LEUKOCARE has relocated its headquarters and R&D facilities to the IZB in Martinsried near Munich, Germany.
LEUKOCARE develops innovative life science technologies in the fields of biopharmaceuticals, drug device combination products, biochemical research products and diagnostic assays.
LEUKOCARE’s Stabilizing and Protecting Solution (SPS) allows to extend shelf life of biologics in dehydrated state and to retain functionality during sterilization by gamma-, beta-radiation or ethylene oxide. LEUKOCARE’s technologies thus enable the design of a new range of products that would not be amenable otherwise, reduce costs, simplify production, and ease regulatory issues.
LEUKOCARE also has expertise in functionalizing a wide variety of surfaces including implant surfaces, wound dressings, patches, stents, catheters, columns for ex-vivo blood treatment and others. LEUKOCARE offers collaborative research and development services with biological and chemical lab capacity to interested partners related to its core competences. LEUKOCARE’s portfolio of patented technologies is available for purchase, licensing or collaborative product development customizing the SPS technologies to the requirements and needs of interested partners.In order to ensure both consistent high quality of its products and services and to comply with ISO standards, LEUKOCARE implemented a Quality Management System and is certified according to DIN EN ISO 9001:2008 and DIN EN ISO 13485:2003.